BACKGROUND:Serotonergic antidepressants [selective serotonin reuptake inhibitor (SSRI)] are first-line treatments for generalised anxiety disorder (GAD); however, it is not known if synaptic serotonin (5-HT) availability is important for SSRI efficacy. The present study tested the hypothesis that temporary reduction in central 5-HT transmission, through acute tryptophan depletion (ATD), would reverse the therapeutic effect of the SSRIs in GAD patients. METHODS:Twelve patients (six males) with GAD, who showed sustained clinical improvement with SSRI treatment, underwent ATD in a double-blind, placebo-controlled, within-subjects design over 2 days, 1 week apart. At the peak time of depletion, the participants inhaled 7.5% CO2 and air in random order for at least 12 min each. Psychological responses were measured using the Spielberger State Anxiety Inventory (STAI-S) and GAD-symptom visual analogue scales (VASs; e.g., worry and tense) and Profile of Mood States. RESULTS:Free plasma tryptophan to large neutral amino acid (LNAA) ratio decreased by 92% on the depletion day and decreased by 2% on the control day. Irrespective of depletion condition, 7.5% CO(2) inhalation significantly increased STAI-S and GAD-related VAS scores (all p < 0.05) compared with air inhalation. ATD had no effect on any of these measures despite the substantial reduction in free tryptophan/LNAA ratio. CONCLUSIONS: Although SSRIs treat GAD effectively, the present results suggest that the mechanism of action is different to that seen in panic, social anxiety, and post-traumatic stress disorders. Successful SSRI treatment of GAD may involve long-term receptor changes or alterations in other neurotransmitter systems downstream of serotonin.
RCT Entities:
BACKGROUND: Serotonergic antidepressants [selective serotonin reuptake inhibitor (SSRI)] are first-line treatments for generalised anxiety disorder (GAD); however, it is not known if synaptic serotonin (5-HT) availability is important for SSRI efficacy. The present study tested the hypothesis that temporary reduction in central 5-HT transmission, through acute tryptophan depletion (ATD), would reverse the therapeutic effect of the SSRIs in GAD patients. METHODS: Twelve patients (six males) with GAD, who showed sustained clinical improvement with SSRI treatment, underwent ATD in a double-blind, placebo-controlled, within-subjects design over 2 days, 1 week apart. At the peak time of depletion, the participants inhaled 7.5% CO2 and air in random order for at least 12 min each. Psychological responses were measured using the Spielberger State Anxiety Inventory (STAI-S) and GAD-symptom visual analogue scales (VASs; e.g., worry and tense) and Profile of Mood States. RESULTS: Free plasma tryptophan to large neutral amino acid (LNAA) ratio decreased by 92% on the depletion day and decreased by 2% on the control day. Irrespective of depletion condition, 7.5% CO(2) inhalation significantly increased STAI-S and GAD-related VAS scores (all p < 0.05) compared with air inhalation. ATD had no effect on any of these measures despite the substantial reduction in free tryptophan/LNAA ratio. CONCLUSIONS: Although SSRIs treat GAD effectively, the present results suggest that the mechanism of action is different to that seen in panic, social anxiety, and post-traumatic stress disorders. Successful SSRI treatment of GAD may involve long-term receptor changes or alterations in other neurotransmitter systems downstream of serotonin.
Authors: Sean D Hood; Dana A Hince; Hayley Robinson; Melita Cirillo; David Christmas; Joey M Kaye Journal: Psychoneuroendocrinology Date: 2006-09-08 Impact factor: 4.905
Authors: Marie Cahir; Tara C Ardis; Jennifer J Elliott; Christopher B Kelly; Gavin P Reynolds; Stephen J Cooper Journal: Eur Neuropsychopharmacol Date: 2007-08-24 Impact factor: 4.600
Authors: Christoph Czermak; Richard Hauger; Wayne C Drevets; David A Luckenbaugh; Marilla Geraci; Dennis S Charney; Alexander Neumeister Journal: J Affect Disord Date: 2008-02-20 Impact factor: 4.839
Authors: Spilios V Argyropoulos; Jayne E Bailey; Sean D Hood; Adrian H Kendrick; Ann S Rich; Gabriel Laszlo; Jon R Nash; Stafford L Lightman; David J Nutt Journal: Psychoneuroendocrinology Date: 2002-08 Impact factor: 4.905
Authors: Francisco A Moreno; Robert P Erickson; Holly A Garriock; Joel Gelernter; Jim Mintz; Jennifer Oas-Terpstra; Marilyn A Davies; Pedro L Delgado Journal: Mol Neuropsychiatry Date: 2015-09-24
Authors: Felix D C C Beacher; Marcus A Gray; Ludovico Minati; Richard Whale; Neil A Harrison; Hugo D Critchley Journal: Psychopharmacology (Berl) Date: 2010-07-02 Impact factor: 4.530
Authors: Alessandro Colasanti; Gabriel Esquivel; Erik den Boer; Annerieke Horlings; Abdul Dandachi; Jeff L Oostwegel; Eva L van Donkelaar; Eric J Griez; Koen Schruers Journal: Psychopharmacology (Berl) Date: 2011-02-19 Impact factor: 4.530
Authors: Simone M E Schopman; Renske C Bosman; Anna D T Muntingh; Anton J L M van Balkom; Neeltje M Batelaan Journal: Transl Psychiatry Date: 2021-02-11 Impact factor: 6.222